FLT3-specific chimeric antigen receptors and methods of using the same
FLT3-specific chimeric antigen receptors address the suboptimal treatment outcomes for leukemia by targeting and destroying cancer cells, enhancing immune responses, and improving survival rates for leukemia patients.
Patent Information
- Application Number
- JP2024112931
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-05-27
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-06
AI Technical Summary
Current treatments for leukemia, particularly in infant pre-B cell precursor acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), have suboptimal survival rates of less than 40% and 60%, respectively, necessitating the development of more effective therapeutic options.
Development of FLT3-specific chimeric antigen receptors (CARs) comprising antigen-binding domains, transmembrane domains, and intracellular T cell signaling domains, including 4-1BB, which can target and destroy leukemia cells by bypassing tumor escape mechanisms and promoting an antigen-specific immune response.
The FLT3-specific CARs effectively target and eliminate leukemia cells, reducing or eliminating cancer cells, promoting immune cell infiltration into tumors, and extending anti-cancer responses, thereby improving treatment outcomes for leukemia patients.
Smart Images

Figure 2024156707000004 
Figure 2024156707000005 
Figure 2024156707000006
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This patent application is a continuation of U.S. Provisional Patent Application No. 62 / 342,394, filed May 27, 2016 (see The present invention claims the benefit of the above-mentioned application, which is hereby incorporated by reference in its entirety.
[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was funded by the National Institutes of Health, National Cancer Institute under project number ZIA BC 011295. This work was made with government support from the Intramural Research Program of the Institute, Cancer Research Center.
[0003] Incorporation by Reference of Electronically Submitted Materials The computer readable nucleotide / amino acid sequence listing, filed concurrently herewith and identified as follows, is incorporated herein by reference in its entirety: 1 file. [Background technology]
[0004] 2. Background of the Invention There remains a subgroup of leukemia patients for whom standard treatment is suboptimal. For example, infant pre-B Patients with cell precursor acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) have survival rates of less than 40% and less than 60%, respectively. Thus, there is an unmet need for additional cancer treatments. Summary of the Invention
[0005] Summary of the Invention An embodiment of the present invention is a method for producing a FLT3-specific antigen-binding domain, a transmembrane domain, and an intracellular T Provided is a chimeric antigen receptor (CAR) comprising a cell signaling domain, which may further comprise a 4-1BB intracellular domain, a spacer, or both. Further embodiments of the invention provide related nucleic acids, recombinant expression vectors, host cells, cell populations, antibodies or antigen-binding portions thereof, and pharmaceutical compositions related to the CARs of the invention. Additional embodiments of the invention provide methods of detecting the presence of a proliferative disorder, eg, cancer, and methods of treating or preventing a proliferative disorder, eg, cancer, in a mammal. [Brief description of the drawings]
[0006] [Figure 1] FIG. 1 is a bar graph showing that FLT3 is expressed on acute lymphoblastic and acute myeloid leukemia cell lines. [Diagram 2] FIG. 2 is a schematic diagram of a CAR according to an embodiment of the present invention. [Diagram 3] FIG. 3 shows flow cytometry graphs of FLT3 CAR T cell transduction according to an embodiment of the invention. [Figure 4] FIG. 4 is a bar graph showing that T cells expressing FLT3-targeting chimeric antigen receptors secrete high levels of interferon gamma when co-cultured with FLT3-expressing ALL cell lines according to an embodiment of the invention. [Diagram 5] FIG. 5 is a bar graph showing that T cells expressing FLT3-targeting chimeric antigen receptors secrete high levels of interleukin-2 when co-cultured with FLT3-expressing ALL cell lines according to an embodiment of the invention. [Figure 6] FIG. 6 is a bar graph showing that T cells expressing FLT3-targeting chimeric antigen receptors secrete high levels of interferon gamma when co-cultured with FLT3-expressing AML cell lines according to an embodiment of the invention. [Figure 7]FIG. 7 is a bar graph showing that T cells expressing FLT3-targeting chimeric antigen receptors secrete high levels of interleukin-2 when co-cultured with FLT3-expressing AML cell lines according to an embodiment of the invention. [Figure 8] FIG. 8 depicts images showing that T cells expressing an FLT3-targeting CAR can reduce FLT3-expressing ALL in vivo, according to an embodiment of the invention. [Figure 9] Figure 9 represents images showing in vivo dose escalation of FLT3 CAR T cells (10x106 cells (column "10"), 5x106 cells (column "5") or 1x106 cells (column "1")) according to an embodiment of the invention. [Figure 10] FIG. 10 depicts images showing that T cells expressing an FLT3-targeting CAR can delay the progression of FLT3-expressing AML in vivo, in accordance with an embodiment of the present invention. [Figure 11] FIG. 11 depicts images showing that T cells expressing an FLT3-targeting CAR can delay the progression of FLT3-expressing AML in vivo, in accordance with an embodiment of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] Detailed Description of the Invention ALL represents a common tumor diagnosis in children. Most patients are cured. Modern chemotherapy for pediatric ALL has made substantial advances. Nevertheless, ALL remains a common cause of cancer death in children, either due to disease recurrence that no longer responds to cytotoxic chemotherapy or due to resistance to current therapies. Furthermore, long-term treatment-induced mortality remains a major problem, especially in patients considered at high risk of relapse and therefore treated with more intensive regimens under current risk-adapted protocols. In adults, ALL is less common than in children. However, the prognosis for adults with ALL is worse than that for children treated with standard cytotoxic chemotherapy. Treatment of young adults with pediatric regimens improves outcome, but not to the level achieved in children.
[0008] Adoptive cell transfer (ADT or ACT) of T cells genetically modified to express chimeric antigen receptors (CARs) that target antigens expressed on lymphoid cells has shown potent activity in B-cell malignancies, including ALL, and has led to remissions in patients refractory to chemotherapy. The surface proteins targeted in the majority of these trials have been shown to be potent antigens in both malignant and non-malignant B The CD19 antigen is expressed on both CD19 and CD3 cells. However, in some cases, loss of CD19 expression has led to relapse rather than remission in all patients. Loss of CD19 expression has also been reported following treatment with bispecific antibody-based agents targeting both CD19 and CD3. has also been observed.
[0009] Patients with infant ALL or AML express high levels of FMS-like tyrosine kinase 3 (FLT3) FLT3 also inhibits Fms-related tyrosine kinase 3, stem cell tyrosine kinase 1, and FL cytokines. FLT3 is also known as the inactivating factor receptor, CD135 antigen, FLK-2, STK1, and fetal liver kinase 2. , which is frequently mutated in AML, leading to activation of the pathway and a major cause of the disease. It is believed to be causative. Thus, downregulation of FLT3 is an unlikely escape mechanism. Furthermore, mutations are found in the intracellular domain of the receptor, so immune cells expressing FLT3 CAR can target both wild-type and mutant FLT3, allowing broad targeting of both infant ALL and AML, and can target any leukemia that overexpresses FLT3.
[0010] One embodiment of the present invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. The CAR binds 4-1BB It may further comprise an intracellular domain, a spacer, or both.
[0011] Chimeric antigen receptors (CARs) are a class of antigen-binding domains of antibodies linked to T cell signaling domains. CARs are artificially constructed hybrid proteins or polypeptides (e.g., single chain variable fragments (scFv)) that contain a domain. A feature of CARs is their ability to utilize the antigen-binding properties of monoclonal antibodies to redirect the specificity and reactivity of T cells to selected targets in an MHC-unrestricted manner. MHC-unrestricted antigen recognition confers on T cells expressing CARs the ability to recognize antigens independent of antigen processing, thus It bypasses a major tumor escape mechanism. Moreover, when expressed in T cells, CARs advantageously do not dimerize with the alpha and beta chains of the endogenous T cell receptor (TCR).
[0012] As used herein, the phrases "having antigen specificity" and "eliciting an antigen-specific response" mean that the CAR can specifically bind to an antigen and immunologically recognize the antigen, such that binding of the CAR to the antigen elicits an immune response.
[0013] Without being bound by any particular theory or mechanism, by inducing an antigen-specific response to FLT3, the CAR of the present invention is capable of: targeting and destroying FLT3-expressing cancer cells; The present invention is believed to provide one or more of the following: reducing or eliminating cancer cells; promoting infiltration of immune cells to the site(s) of the tumor; and promoting / extending an anti-cancer response. do.
[0014] One embodiment of the present invention is directed to an antibody, e.g., NC7, that is based on an antigen-binding domain specific for FLT3. The present invention provides a CAR comprising a light chain variable region and a heavy chain variable region. NC7 is described in U.S. Patent No. 8,071,099, the entirety of which is incorporated herein by reference. The scFv comprises a light chain variable region and a heavy chain variable region. In an embodiment of the invention, the light and heavy chains may be, for example, any of the light and heavy chains listed in Table 1 below. The sequence may include any suitable combination of the following sequences:
[0015] In one embodiment, the CAR may have multispecific antigen-binding domains. For example, the CAR can target FLT3 and at least one other target, e.g., CD19 or CD20 for ALL. The antibody may be specific for a leukemia target such as CD22 for example, or CD33 or CD123 for AML.
[0016] In one embodiment, the antigen binding domain comprises a linker. The linker links the heavy chain variable region and the light chain variable region of the antigen binding domain. Any linker suitable for linking the heavy chain variable region and the light chain variable region may be used in the antigen binding domain of the present invention. In one embodiment, the linker comprises a glycine-serine linker domain or Preferably, the antigen-binding domain comprises an scFv comprising a heavy chain variable region, a light chain variable region and a linker. In an embodiment of the invention, the light chain, the heavy chain and the linker are any of the light chain, heavy chain and linker sequences listed in Table 1 below. It may include any suitable combination of the above.
[0017] In one embodiment of the present invention, the CAR comprises: MLLVTSLLLCELPHPAFLLIPEVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCATFAL FGFREQAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDLATYY CQQSYSTPFTFGPGTKVDIKSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 1) The amino acid sequence may comprise, consist of, or consist essentially of the sequence:
[0018] In another embodiment of the invention, the CAR comprises: MLLVTSLLLCELPHPAFLLIPEVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCATFALFGFREQAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCR ASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQSYSTPFTFGPGTKVDIKSGLEDPAEPKSPDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKKDPKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 2) The amino acid sequence may comprise, consist of, or consist essentially of the sequence:
[0019] In one embodiment, the antigen binding domain comprises a leader / signal sequence. The leader sequence may be located at the amino terminus of the heavy chain variable region. The leader sequence may comprise any suitable leader sequence. In an embodiment of the invention, the leader / signal sequence is , may comprise a sequence listed below in Table 1. In mature forms of T cells, the leader sequence may be absent.
[0020] In one embodiment of the invention, the CAR comprises a transmembrane domain. In this case, the transmembrane domain comprises CD8. CD8 is a CD8α (CD8 alpha) hinge and transmembrane domain. In a preferred embodiment, the CD8 is human. The CD8 may comprise less than a complete CD8 domain. In an embodiment of the invention, the CD8 comprises a domain listed in Table 1 below. It may include the sequences described above.
[0021] In one embodiment of the invention, the CAR comprises an intracellular T cell signaling domain comprising 4-1BB (CD137), CD3 zeta (ζ), or both. In a preferred embodiment, the CD3 zeta, 4-1BB, or both are human. 4-1BB provides a potent costimulatory signal to T cells. CD3ζ associates with the TCR to generate a signal and contains an immunoreceptor tyrosine-based activation motif (ITAM). In one embodiment, the CAR lacks the 4-1BB domain. In another embodiment, the CAR contains a CD28 domain. CD28 is a T cell marker important in T cell costimulation. 4-1BB, CD28, CD3 zeta, or any of these may comprise less than the complete 4-1BB or CD3 zeta, respectively. In an embodiment of the invention, 4-1BB may comprise a sequence listed in Table 1 below. In an embodiment of the invention, CD3 zeta may comprise a sequence listed in Table 1 below.
[0022] In one embodiment of the invention, the CAR comprises a spacer. The spacer may be any of the above-described In one embodiment, the CAR comprises an IgG heavy chain constant domain (CH2CH3) spacer. In a further embodiment, the spacer can be between the scFv and the transmembrane domain. In a preferred embodiment, the spacer, e.g., the CH2CH3 sequence, is human. In an embodiment of the invention, the spacer comprises a sequence listed in Table 1 below. It may include. Embodiments of the invention include the sequences provided in Table 1 below.
[0023] [Table 1]
[0024] Embodiments of the invention include the following sequences in Table 2, including those shown in Table 1 above.
[0025] [Table 2]
[0026] Embodiments of the invention include the following sequences in Table 3, including those shown in Table 1 above, where no signal peptide is present.
[0027] [Table 3]
[0028] The scope of the present invention includes functional portions of the CARs of the invention described herein. When used in reference to a CAR, the term "functional portion" refers to any portion or fragment of a CAR of the invention, where the portion or fragment retains the biological activity of the CAR of which it is a portion (the parent CAR). A functional portion refers to, for example, a fragment of a parent CAR that is similar to, the same as, or better than the parent CAR. In some embodiments, a functional portion of a CAR comprises a portion of a CAR that retains to a greater extent the ability to recognize a target cell or to detect, treat, or prevent a disease. With respect to a parent CAR, a functional portion can comprise, for example, about 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95% or more of the parent CAR.
[0029] A functional portion may contain additional amino acids at the amino or carboxy terminus of the portion, or at both termini, that are not found in the amino acid sequence of the parent CAR. Desirably, the additional amino acids do not interfere with the biological function of the functional moiety, e.g., recognizing a target cell, detecting cancer, treating or preventing cancer, etc. More desirably, the additional amino acids enhance the biological activity of the functional moiety compared to the biological activity of the parent CAR.
[0030] The scope of the present invention includes functional variants of the CAR of the present invention described herein. As used herein, the term "functional mutant" refers to a mutant that is a functional mutant of CAR (the function of the mutant). A functional variant is a variant that retains the biological activity of the variant and has a substantial or significant similarity to the parent CAR. It refers to a CAR, polypeptide, or protein that has significant sequence identity or similarity to a CAR. Potent variants may, for example, bind to target cells to a similar extent, to the same extent, or to a greater extent than the parent CAR. The present invention encompasses variants of the CARs described herein (parent CARs) that retain the ability to recognize cells. With respect to the parent CAR, a functional variant can be, for example, at least about 30%, 50%, 75%, 80%, 90%, 98% or more identical in amino acid sequence to the parent CAR.
[0031] A functional variant can, for example, comprise the amino acid sequence of a parent CAR with at least one conservative amino acid substitution. Alternatively or additionally, a functional variant can comprise at least one non-conservative amino acid substitution. In this case, the amino acid sequence of the parent CAR may include the amino acid sequence of the parent CAR with a complementary amino acid substitution. It is preferred that non-conservative amino acid substitutions do not interfere with or inhibit the biological activity of the functional variant. Non-conservative amino acid substitutions may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is enhanced compared to the parent CAR.
[0032] The amino acid substitutions in the CAR of the present invention are preferably conservative amino acid substitutions. Amino acid substitutions are known in the art and involve the replacement of one amino acid having certain physical and / or chemical properties with another amino acid having the same or similar chemical or physical properties. For example, conservative amino acid substitutions include substitutions of amino acids that are substituted with other acidic / negatively charged polar amino acids (e.g., Asp or Glu), substitutions of amino acids with non-polar side chains with other non-polar side chains (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.), substitutions of basic / positively charged polar amino acids with other basic / positively charged polar amino acids, etc. Positively charged polar amino acids (e.g., Lys, His, Arg, etc.) are substituted, and uncharged amino acids with polar side chains are The substitution may be an amino acid having a polar side chain that is uncharged (e.g., Asn, Gln, Ser, Thr, Tyr, etc.), an amino acid having a β-branched side chain that is substituted with an amino acid having a different β-branched side chain (e.g., Ile, Thr, and Val), an amino acid having an aromatic side chain that is substituted with an amino acid having an aromatic side chain (e.g., His, Phe, Trp, and Tyr), etc.
[0033] Amino acids may also be added or removed from the sequence based on the design of the vector. For example, the amino acids (SEQ ID NO:20) added for the design of the vector are removed from the CAR sequence in Table 2, Table 3, or both, as described herein. may be removed from the CAR.
[0034] CAR is a variant of the CAR in which other components, e.g., other amino acids, substantially confer biological activity to the functional variant. Without modification, it may consist essentially of the specific amino acid sequence or sequences set forth herein.
[0035] The CARs (including functional portions and functional variants) of the present embodiments can be of any length. That is, the CAR (or a functional portion or functional variant thereof) is, e.g., antigen-specific. CARs can contain any number of amino acids, provided that they retain biological activity, such as the ability to bind to a target cell, detect diseased cells in a mammal, or treat or prevent disease in a mammal. For example, a CAR can be about 50 to about 5000 amino acids in length, such as 50, 70, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids in length. It is possible.
[0036] The CAR of the present embodiment (including functional portions and functional variants of the present invention) may contain synthetic amino acids in place of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino-n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-aminomethyl-cysteine, α-amino-n-decanoic acid ... 3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenyl Alanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylse Phosphorus β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexyl Cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetramethylphenyl tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentanecarboxylic acid, α-aminocyclohexanecarboxylic acid, α- Aminocycloheptane carboxylic acid, α-(2-amino-2-norbornane)-carboxylic acid, α,γ- These include diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine.
[0037] The CARs (including functional portions and functional variants) of the present invention are glycosylated, aryl, or aryl-peptide-binding domains. They may be midated, carboxylated, phosphorylated, esterified, N-acylated, cyclized (e.g., via disulfide bridges), or converted into acid addition salts and / or optionally dimerized or polymerized, or conjugated.
[0038] The CARs of the present embodiments (including functional portions and functional variants thereof) are described in the art. CAR can be obtained by methods known in the art. The polypeptides and proteins may be produced by any suitable method. Suitable methods for novo synthesis are described in references such as Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press (Oxford, UK), 2000; Peptide and Protein Drug Analysis, Reid, R. (ed.), Marcel Dekker & Co., 2000; Epitope Mapping, Westwood et al. (eds.), Oxford University Press (Oxford, UK), 2001; and U.S. Pat. No. 5,449,752. Polypeptides and proteins may also be produced recombinantly using the nucleic acids described herein using standard recombinant methods. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd ed.) Cold Spring Harbor Press (Cold Spring Harbor, NY) 2001; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons (NY) 1994. Additionally, some of the CARs of the invention (including functional portions and functional variants thereof) can be expressed in, for example, plants, bacteria, The CARs may be isolated and / or purified from sources such as insects, mammals, e.g., rats, humans, etc. Methods of isolation and purification are well known in the art. Alternatively, the CARs described herein (including functional portions and functional variants thereof) may be commercially synthesized by companies. In this regard, the CAR of the present invention can be synthetic, recombinant, isolated and / or purified.
[0039] One embodiment of the present invention is an antibody or its antibody that specifically binds to an epitope of the CAR of the present invention. The original binding moiety is further provided. The antibody can be any type of immunoglobulin known in the art. For example, the antibody can be of any isotype, e.g., IgA, IgD, IgE, IgG, IgM, etc. The antibody can be monoclonal or polyclonal. The antibody may be a naturally occurring antibody, e.g., an antibody isolated and / or purified from a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human, etc. Alternatively, the antibody may be a genetically modified antibody, e.g., a humanized antibody or a chimeric antibody. The antibody may be in monomeric or multimeric form. The antibody may also be capable of binding to any level of a functional portion of the CAR of the invention. The affinity or avidity of the antibody may be 0.01 to 0.1.
[0040] Methods for testing the ability of an antibody to bind to any functional portion of the CAR of the invention are known in the art. Any antibody-antigen binding assay known in the art, such as, for example, radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, and competitive inhibition assays, can be used. (See, e.g., Janeway et al. (infra), U.S. Patent Application Publication No. 2002 / 0197266 A1, and U.S. Patent No. 7,338,929).
[0041] Suitable methods for producing antibodies are known in the art. For example, standard hybridoma methods are described, e.g., in Kohler and Milstein, Eur. J. Immunol., 5, 511-519 (1976), in Harlow and Lane (eds.) Antibodies: A Laboratory Manual, CSH Press (1988), and in CA Janeway et al. (eds.) Immunobiology (5th ed.) Garland Publishing (New York, NY) (2001). Alternatively, other methods are known in the art, such as the EBV hybridoma method (Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984), and Roder et al., Methods Enzymol., 121, 140-67 (1986)), and bacteriophage vector expression systems (see, e.g., Huse et al., Science, 246, 1275-81 (1989)). Additionally, methods for producing antibodies in non-human animals are described, e.g., in U.S. Pat. Nos. 5,545,806, 5,569,825, and 5,714,352, U.S. Patent Application Publication No. 2002 / 0197266 A1, and U.S. Pat. No. 7,338,929.
[0042] Additionally, phage display can be used to generate antibodies. In this regard, phage libraries encoding antigen-binding variable (V) domains of antibodies can be used to generate standard molecules. These antibodies can be produced using biology and recombinant DNA technology (see, e.g., Sambrook et al., supra, and Ausubel et al., supra). Phage encoding variable regions with the desired specificity are selected for specific binding to the desired antigen, and complete or partial antibodies are rearranged to contain the selected variable domains. The nucleic acid sequences encoding the rearranged antibodies are introduced into a suitable cell line, such as myeloma cells used for hybridoma production, so that antibodies with the properties of a monoclonal antibody are secreted by the cells (see, e.g., Janeway et al., supra, Huse et al., supra, and (See U.S. Patent No. 6,265,150).
[0043] Antibodies can be produced by transgenic mice that are transgenic for particular heavy and light chain immunoglobulin genes. Such methods are known in the art and are described, for example, in U.S. Patent Nos. 5,545,806 and 5,569,825, and in Janeway et al. (supra).
[0044] Methods for producing humanized antibodies are well known in the art and are described in detail, for example, in Janeway et al. (supra), U.S. Patent Nos. 5,225,539, 5,585,089 and 5,693,761, European Patent No. 0239400 B1, and British Patent No. 2188638. Targeted antibodies can also be generated using the antibody resurfacing techniques described in US Pat. No. 5,639,641 and in Pedersen et al., J. Mol. Biol., 235, 959-973 (1994).
[0045] One embodiment of the present invention also provides an antigen-binding portion of any of the antibodies described herein. Antigen-binding portions include Fab, F(ab')2, dsFv, sFv, diabodies and tribodies. It may be any moiety that has at least one antigen binding site, such as triabodies.
[0046] Single chain variable region fragments (antibody fragments) can be synthesized using conventional recombinant DNA technology. Disulfide esters can be produced using glycerol technology (see, e.g., Janeway et al., supra). Stabilized variable region fragments can be prepared by recombinant DNA techniques (see, e.g., Reiter et al., Protein Engineering, 7, 697-704 (1994)). However, the antibody fragments of the present invention are not limited to these exemplary types of antibody fragments.
[0047] Additionally, the antibodies or antigen-binding portions thereof may be modified to contain a detectable label (e.g., radioisotopes, fluorophores (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), enzymes (e.g., alkaline phosphatase, horseradish peroxidase), and elemental particles (e.g., gold particles), etc.).
[0048] According to one embodiment of the present invention, the CARs described herein (including their functional parts and functions) are Further provided are nucleic acids comprising a nucleotide sequence encoding any one of the The nucleic acids of the invention include nucleotides encoding any of the leader sequences, antigen binding domains, transmembrane domains, and / or intracellular T cell signaling domains described herein. It may contain a tid sequence.
[0049] In some embodiments, the nucleotide sequence may be codon-optimized. Without being bound by any particular theory, it is believed that the codon optimization of the nucleotide sequence increases the translation efficiency of the mRNA transcript. The codon optimization of the nucleotide sequence may include replacing native codons with other codons that code for the same amino acid but can be translated by tRNAs that are more readily available in cells, thus increasing translation efficiency. The optimization of the nucleotide sequence may also reduce the secondary structure of the mRNA that interferes with translation, thus increasing translation efficiency.
[0050] In one embodiment of the invention, the nucleic acid encodes the antigen-binding domain of the CAR of the invention. In another embodiment of the invention, a nucleic acid can comprise a codon-optimized nucleotide sequence encoding any of the CARs described herein (including functional portions and functional variants thereof).
[0051] As used herein, "nucleic acid" includes "polynucleotides", "oligonucleotides" and "nucleic acid molecules" and generally refers to polymers of DNA or RNA, which may be single-stranded or double-stranded, may be synthetic or obtained from natural sources (e.g., isolated and / or purified), may contain natural, non-natural or modified nucleotides, and may contain modified internucleotide linkages, such as phosphoramidite or phosphorothioate linkages, in place of natural linkages, non-natural linkages or phosphodiester linkages found between nucleotides of unmodified oligonucleotides. In some embodiments, the nucleic acid does not contain any insertions, deletions, inversions and / or substitutions. However, as discussed herein, in some instances, it may be preferred for the nucleic acid to contain one or more insertions, deletions, inversions and / or substitutions.
[0052] The nucleic acid of one embodiment of the present invention may be recombinant. As used herein, the term "recombinant" refers to a nucleic acid molecule that (i) is capable of being replicated in a living cell, and (ii) is a nucleic acid sequence that has been modified from a natural or synthetic nucleic acid molecule. or (ii) a molecule constructed by ligating fragments of the nucleic acid sequence described in (i) above outside of a living cell. For the purposes of this specification, replication may be in vitro or in vivo.
[0053] Recombinant nucleic acids have a sequence that does not occur in nature or where two sequences would not be distinct without recombination. Nucleic acids may have sequences created by the artificial combination of isolated segments, which is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acid, e.g., by genetic engineering techniques such as those described in Sambrook et al., supra. Nucleic acids can be constructed based on chemical synthesis and / or enzymatic ligation reactions, using procedures known in the art. See, e.g., Sambrook et al., supra, and Ausubel et al., supra. For example, nucleic acids can be derived from naturally occurring nucleosides. Nucleic acids can be chemically synthesized using uracil, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-chlorouracil-substituted nucleotides, or a variety of modified nucleotides (e.g., phosphorothioate derivatives and acridine-substituted nucleotides) designed to increase the biological stability of the molecule or to enhance the physical stability of the duplex formed upon hybridization. Examples of modified nucleotides that can be used to generate nucleic acids include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-chlorouracil-substituted nucleotides ... 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-( 5-(carboxyhydroxymethyl) uracil, 5-cal 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil , dihydrouracil, beta-D-galactosylqueosine, inosine, N 6 -Isopentenyladenine (N 6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine , 5-methylcytosine, N 6 -Substituted adenine (N 6 -Substituted adenine ), 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-meth 5'-methoxycarboxymethyluracil, 5-methoxyuracil 5-methoxyuracil, 2-methylthio-N 6 -Isopentenyladenine (2-methylthio-N 6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl)uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the invention can be, for example, These can be purchased from companies such as Integrated DNA Technologies (Coralville, IA, USA).
[0054] The nucleic acid encodes a CAR or a functional portion or variant thereof. It may comprise any isolated or purified nucleotide sequence. Alternatively, the nucleotide sequence may comprise a nucleotide sequence that is degenerate to any of the sequences, or a combination of degenerate sequences.
[0055] One embodiment of the present invention also provides an isolated or purified nucleic acid comprising a nucleotide sequence that is complementary to the nucleotide sequence of any of the nucleic acids described herein, or that hybridizes under stringent conditions to the nucleotide sequence of any of the nucleic acids described herein.
[0056] Nucleotide sequences that hybridize under stringent conditions may hybridize under high stringency conditions. By "high stringency conditions" is meant that the nucleotide sequence specifically hybridizes to a target sequence (any nucleotide sequence of the nucleic acids described herein) in an amount that is detectably stronger than non-specific hybridization. High stringency conditions include a wide variety of hybridization conditions, ranging from random sequences that happen to have only a few small regions (e.g., 3-10 bases) that match the nucleotide sequence to exactly complementary sequences. These conditions include conditions that distinguish between polynucleotides with identical sequences or polynucleotides containing only scattered minor mismatches. Such small regions of complementarity melt more easily than full-length complements of 14-17 bases or more, and they can be easily distinguished by high stringency hybridization. Relatively high stringency conditions include low salt and / or high temperature conditions, e.g., provided by about 0.02-0.1 M NaCl or equivalent, at a temperature of about 50-70°C. Such high stringency conditions tolerate few, if any, mismatches between the nucleotide sequence and the template or target strand, and are particularly suitable for detecting the expression of any of the CARs of the present invention. Formamide It is generally understood that conditions can be made more stringent by adding increasing amounts of the compound.
[0057] The present invention also relates to a nucleic acid sequence that is at least about 70% or more similar to any of the nucleic acids described herein. In one embodiment, the nucleic acid comprises a nucleotide sequence that is, for example, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical to the nucleic acid sequence of the first or second nucleotide.
[0058] In one embodiment, the nucleic acid of the invention can be incorporated into a recombinant expression vector. In this regard, one embodiment of the invention provides a recombinant expression vector comprising any of the nucleic acids of the invention. For the purposes of this specification, the term "recombinant expression vector" refers to a genetically modified oligonucleotide or polynucleotide construct that allows expression of the mRNA, protein, polypeptide or peptide by a host cell, when the construct comprises a nucleotide sequence encoding an mRNA, protein, polypeptide or peptide and the vector is contacted with the cell under conditions sufficient to express the mRNA, protein, polypeptide or peptide in the cell. The vector of the invention is not naturally occurring as a whole. However, portions of the vector may be naturally occurring. The recombinant expression vector of the invention may comprise any type of nucleotide, including but not limited to DNA and RNA, which may be single-stranded or double-stranded, synthetic or partially obtained from natural sources, and may include natural, non-natural or modified nucleotides. The recombinant expression vector may include naturally occurring internucleotide bonds, non-naturally occurring internucleotide bonds, or both types of bonds. Preferably, the non-naturally occurring or modified nucleotides or internucleotide bonds do not interfere with the transcription or replication of the vector.
[0059] In one embodiment, the recombinant expression vector of the invention can be any suitable recombinant expression vector and can be used to transform or transfect any suitable host cell. Suitable vectors include those designed for propagation and expansion or for expression, or both, such as plasmids and viruses. The vector may be selected from the group consisting of the pUC series (Fermentas Life Sciences, Glen Burine, MD), the pBluescript series (Stratagene, LaJolla, CA), the pET series (Novagen, Madison, WI), the pGEX series (Pharmacia Biotech, Uppsala, Sweden) and the pEX series (Clonetech, Palo Alto, CA). Bacteriophage vectors, such as λGT10 , λGT11, λZapII (Stratagene), λEMBL4, and λNM1149, etc. can also be used. Examples of plant expression vectors include pBI01, pBI101.2, pBI101.3, pBI121, and pBIN19 (Clonetech). Examples of animal expression vectors include pEUK-C1, pMAM, and pMAMneo (Clonetech). The recombinant expression vector can be a viral vector, e.g., a retroviral vector or a lentiviral vector.
[0060] Many transfection techniques are generally known in the art (e.g. See, Graham et al., Virology, 52:456-467 (1973); Sambrook et al., supra; Davis et al., Basic Methods in Molecular Biology, Elsevier (1986); and Chu et al., Gene, 13:97 (1981). Transfection methods include calcium phosphate co-precipitation (see, e.g., Graham et al., supra), direct microinjection into cultured cells (see, e.g., Capecchi, Cell, 22:479-488 (1980)), electroporation (see, e.g., Shigekawa et al., BioTechniques, 6:742-751 (1988)), liposome-mediated gene transfer (see, e.g., Mannino et al., BioTechniques, 6:682-690 (1988)), lipid-mediated transduction (see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)), and nucleic acid delivery using high-velocity microprojectiles (see, e.g., Klein et al., Nature, 327:70-73 (1987)).
[0061] In one embodiment, the recombinant expression vectors of the invention can be prepared using standard recombinant DNA techniques, for example, as described in Sambrook et al. (supra) and Ausubel et al. (supra). The expression vector constructs, which can be circular or linear, can be prepared to contain a replication system that is functional in a prokaryotic or eukaryotic host cell. Replication systems can include, for example, ColE1, 2μ plus. They may be derived from mid, lambda, SV40, bovine papilloma virus, and the like.
[0062] Recombinant expression vectors, as appropriate, may include control sequences, such as transcriptional and translational initiation and termination codons, specific for the type of host cell (e.g., bacterial, fungal, plant or animal) into which the vector will be introduced, considering whether the vector is DNA- or RNA-based. Recombinant expression vectors may include restriction enzyme recognition sites to facilitate cloning.
[0063] The recombinant expression vector may contain one or more marker genes to allow for the selection of transformed or transfected host cells. Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in auxotrophic hosts to provide prototrophy, etc. Suitable marker genes for the expression vectors of the present invention include, for example, the neomycin / G418 resistance gene, the hygromycin resistance gene, the histidinol resistance gene, the tetracycline resistance gene and the ampicillin resistance gene.
[0064] The recombinant expression vector encodes a CAR (including functional portions and functional variants thereof). or a nucleotide sequence encoding a CAR. The promoter may comprise a native or non-native promoter operably linked to a nucleotide sequence that hybridizes with or is hybridized to the nucleotide sequence. The selection of a promoter, e.g., strong, weak, inducible, tissue specific, and developmental stage specific, is within the ordinary skill of one in the art. Similarly, the combination of a nucleotide sequence with a promoter is within the ordinary skill of one in the art. The promoter may be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter. ) promoter, SV40 promoter, RSV promoter, or mouse stem cell virus long-chain The promoter may be one found in the short terminal repeat.
[0065] The recombinant expression vectors of the invention can be designed for either transient expression, stable expression, or both, and can be made for constitutive or inducible expression.
[0066] Additionally, the recombinant expression vector can be made to contain a suicide gene. As used herein, the term "suicide gene" refers to a gene that kills a cell that expresses the suicide gene. A suicide gene can be a gene that confers sensitivity to a reagent, e.g., a drug, on a cell that expresses the gene, causing the cell to die when the cell is contacted or exposed to the reagent. Suicide genes are known in the art (see, e.g., Suicide Gene Therapy: Methods and Reviews, Springer, Caroline J. (Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, UK), Humana Press, 2004), and include, for example, herpes simplex virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphodiesterase (PND) gene, and cytosine daminase (CdA) gene. lyase and nitroreductase.
[0067] The scope of the present invention includes conjugates, e.g., bioconjugates, comprising the CARs of the present invention (including any of their functional portions or variants), nucleic acids, recombinant expression vectors, host cells, host cell populations, or antibodies or antigen-binding portions thereof. Conjugates and methods for synthesizing conjugates are generally known in the art (see, e.g., Hudecz, F., Methods Mol. Biol. 298:209-223 (2005), and Kirin et al., Inorg Chem. 44(15):5405-5415 (2005)). The CARs of the present invention may be conjugated to a toxin, e.g., toxic to cancer cells.
[0068] One embodiment of the present invention further provides a host cell comprising any of the recombinant expression vectors described herein. As used herein, the term "host cell" refers to any type of cell that can contain a recombinant expression vector of the present invention. A host cell is a eukaryotic cell, e.g., The host cell may be a plant, animal, fungus or algae, or may be a prokaryotic cell, e.g., a bacterium or a protozoan. The host cell may be a cultured cell or a primary cell, i.e., directly isolated from an organism, e.g., a human. The host cell may be an adherent cell or a suspension cell, i.e., a cell that grows in a suspension. Suitable host cells are known in the art, e.g., DH5α E. coli cells, Chinese Ha Examples of recombinant expression vectors include mouse ovary cells, monkey VERO cells, COS cells, and HEK293 cells. For purposes of amplifying or replicating the vector, the host cell can be a prokaryotic cell, e.g., a DH5α cell. For purposes of producing a recombinant CAR, the host cell can be a mammalian cell. The host cells can be human cells. While the host cells can be of any cell type, derived from any type of tissue, and at any stage of development, the host cells can be peripheral blood lymphocytes (PBLs) or peripheral blood mononuclear cells (PBMCs). (PBMC). The host cell may be a T cell.
[0069] For purposes herein, a T cell can be any T cell, such as a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupT1, etc., or a T cell obtained from a mammal. If obtained from a mammal, the T cell may be derived from blood, bone marrow, lymph nodes, thymus, or other tissue. The T cells can be obtained from a number of sources, including, but not limited to, tissues or body fluids of a human. The T cells can also be enriched or purified. The T cells can be human T cells. The T cells can be T cells isolated from a human. The T cells can be CD4 + / CD8 + Double positive T cells, CD4 + Helper T Thin cells, e.g., Th1 and Th2 cells, CD8 +The T cells may be of any type and at any stage of development, including, but not limited to, T cells (e.g., cytotoxic T cells), tumor infiltrating cells, memory T cells, naive T cells, etc. T cells are CD8 + T cells or CD4 + It may be a T cell.
[0070] In one embodiment, a CAR, as described herein, may be used in a suitable non-T cell, such as, for example, a cell with immune effector function, such as, for example, a NK cell, and a T cell-like cell generated from a pluripotent stem cell.
[0071] According to one embodiment of the present invention, a cell line comprising at least one host cell as described herein is provided. A population of cells is also provided. The population of cells may be expressed by at least one other cell, e.g., a recombinant expression vector. Host cells that do not contain any of the following: The cell population may be a heterogeneous population comprising host cells comprising any of the described recombinant expression vectors, as well as phage, neutrophils, red blood cells, hepatocytes, endothelial cells, epithelial cells, muscle cells, brain cells, etc. Alternatively, the cell population may be a substantially homogenous population, where the population comprises primarily (e.g., consists essentially of) host cells comprising the recombinant expression vector. The population may also be a clonal population of cells, where all cells of the population are clones of a single host cell comprising the recombinant expression vector, such that all cells of the population comprise the recombinant expression vector. In one embodiment of the present invention, the cell population is a clonal population comprising host cells comprising the recombinant expression vectors described herein.
[0072] CARs (including functional portions and variants thereof), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and antibodies (including antigen-binding portions thereof), all of which are hereinafter referred to as " The anti-CAR materials of the present invention (collectively referred to as "anti-CAR materials") may be isolated and / or purified. As used herein, the term "isolated" means removed from its natural environment. The terms "purified" or "isolated" do not require complete purification or isolation; rather, they are intended as relative terms. Thus, for example, a purified (or isolated) host cell preparation is one in which the host cells are more pure than the cells in their natural environment in the body. Such host cells can be produced, for example, by standard purification techniques. In some embodiments, the host cells represent at least about 50% of the total cell content of the preparation. The preparation of host cells is purified, e.g., to be at least about 70% pure. The degree may be at least about 50%, may be greater than about 60%, about 70%, or about 80%, or may be about 100%.
[0073] The CAR material of the present invention may be formulated into a composition, such as a pharmaceutical composition. One embodiment of the invention relates to CARs, functional portions, functional variants, nucleic acids, expression vectors, host cells, The present invention also provides a pharmaceutical composition comprising any of the CAR materials of the present invention (including populations thereof), and antibodies (including antigen-binding portions thereof), and a pharma- ceutical acceptable carrier. The pharmaceutical compositions of the invention may contain more than one CAR material of the invention, e.g., a CAR and a nucleic acid, or two or more different CARs. Alternatively, the pharmaceutical composition may contain, for example, asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc. The present invention also provides a method for treating cancer, comprising administering to a patient a therapeutically effective amount of the CAR material of the present invention in combination with other medicaments or drugs, such as chemotherapeutic agents. In a preferred embodiment, the pharmaceutical composition comprises the host cell of the invention or a population thereof.
[0074] The CAR material of the present invention may be provided in the form of a salt, e.g., a pharma- ceutically acceptable salt. Pharmaceutically acceptable acid addition salts include those derived from mineral acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, and sulfuric acid, and from organic acids such as, for example, tartaric acid, acetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid, succinic acid, and arylsulfonic acids, e.g., p-toluenesulfonic acid.
[0075] For pharmaceutical compositions, the pharma- ceutically acceptable carrier may be any of those conventionally used, limited only by chemical and physical considerations, such as solubility and lack of reactivity with the active agent(s), and the route of administration. Pharmaceutically acceptable carriers described herein, such as vehicles, adjuvants, excipients and diluents, are well known to those skilled in the art and are readily available to the public. Pharmaceutically acceptable carriers are preferably those that are chemically inert to the active agent(s) and have no adverse side effects or toxicity under the conditions of use.
[0076] The choice of carrier will be determined in part by the particular CAR material of the present invention and by the particular method used to administer the CAR material of the present invention. Accordingly, there are a variety of suitable formulations of the pharmaceutical compositions of the present invention. Preservatives may be used. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. Mixtures of two or more preservatives may optionally be used. The preservative or mixtures thereof are typically Typically, it is present in an amount of from about 0.0001% to about 2% by weight of the total composition.
[0077] Suitable buffers may include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. Mixtures of two or more buffers are optionally used. The buffering agent or mixture thereof may be used in an amount of typically from about 0.001% by weight to about 4% by weight of the total composition. % by volume.
[0078] The concentration of the CAR material of the present invention in a pharmaceutical formulation may range, for example, from less than about 1% by weight, typically about 10% by weight, or at least about 10% by weight, and preferably from about 20% by weight to about 50% by weight or more, depending on the particular mode of administration selected. The amount of water that can be added may vary from 0.1 to 100% and may be selected primarily depending on the amount and viscosity of the liquid.
[0079] Methods for preparing administrable (e.g., parenterally administrable) compositions are known or will be apparent to those skilled in the art, and are described, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st Edition (May 1, 2005). It is described in more detail.
[0080] The following formulations for oral, aerosol, parenteral (e.g., subcutaneous, intravenous, intraarterial, intramuscular, intradermal, intraperitoneal, and intrathecal) and topical administration are merely illustrative and in no way limiting. More than one route may be used to administer the CAR materials of the invention, and in some cases, a particular route may provide a more rapid and effective response than another route.
[0081] Formulations suitable for oral administration include (a) dilute solutions such as water, saline, or orange juice; (b) liquid solutions, such as an effective amount of the CAR material of the present invention, dissolved in a diluent; (b) capsules, sachets, tablets, lozenges, each containing a predetermined amount of the active ingredient as a solid or granules. (c) powders; (d) suspensions in suitable liquids; and (e) suitable emulsions. The liquid formulation may be, or may consist of, water and diluents such as alcohols, e.g., ethanol, benzyl alcohol, and polyethylene alcohols, with or without the addition of a pharma- ceutically acceptable surfactant. Capsule forms may be of the usual hard or soft shell gelatin type, containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms may contain one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffers, disintegrants, wetting agents, preservatives, flavoring agents, and other pharma- ceutically compatible excipients. The lozenge form contains the CAR material of the present invention in flavorings (usually sucrose and acacia or tragacanth). Similarly, lozenges containing the CAR material of the present invention in an inert base such as gelatin and glycerin, or sucrose and acacia, emulsions and gels, and the like, in addition to including excipients known in the art.
[0082] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may contain suspending agents, solubilizers, thickening agents, stabilizers and preservatives. The CAR material of the present invention may be administered in the presence of pharma- ceuticals such as pharmacopoeias, soaps or detergents, or in the presence of other suitable agents. For example, sterile liquids or mixtures including water, saline, aqueous dextrose and related sugar solutions, with or without the addition of surfactants such as pectin, carbomer, methylcellulose, hydroxypropylmethylcellulose or carboxymethylcellulose, suspending agents, or emulsifying agents and other pharmaceutical adjuvants, alcohols such as ethanol or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, dimethyl sulfoxide, glycerol, ketals such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, poly(ethylene glycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides. The compound may be administered in a physiologically acceptable diluent in a pharmaceutical carrier such as celide.
[0083] The oil that can be used in parenteral formulations includes petroleum, animal, vegetable or synthetic oils.Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum and mineral.Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid and isostearic acid.Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
[0084] Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium and triethanolamine salts, and suitable surfactants include (a) cationic (b) anionic surfactants such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, etc.; (c) nonionic surfactants, such as, for example, fatty amines. oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, etc.; (d) amphoteric surfactants, such as, for example, alkyl-β-aminopropionates, and 2- Alkyl-imidazoline quaternary ammonium salts, etc., and (e) mixtures thereof. .
[0085] Typically, parenteral formulations will contain, for example, about 0.5% to about 25% by weight of the CAR material of the present invention in solution. Preservatives and buffers may be used. To minimize or eliminate irritation at the injection site, such compositions may include one or more non-ionic surfactants, for example, having a hydrophilic-lipophilic balance (HLB) of about 12 to about 17. The surfactants in such formulations may be used in combination with other surfactants, such as glycerol, glycerol, terpenes, or other surfactants. The amount of surfactant typically ranges, for example, from about 5% to about 15% by weight. Examples include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate, and the higher molecular weight adducts of ethylene oxide with hydrophobic bases formed by condensation of propylene oxide and propylene glycol. Parenteral formulations may be presented in unit dose or multiple doses in hermetically sealed containers, such as ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid excipient, such as water, immediately prior to use for injection. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
[0086] Injectable formulations are in accordance with one embodiment of the present invention. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those skilled in the art (see, e.g., Pharmaceutics and Pharmacy Practice, JB Lippincott Company, Philadelphia, PA, Eds. Banker and Chalmers, pp. 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel (4th ed.) pp. 622-630 (1986)).
[0087] Topical formulations, including those useful for transdermal drug delivery, are well known to those of skill in the art and are suitable for application to the skin in the context of the embodiments of the invention. The aerosol formulations may be combined with the appropriate components to produce aerosol formulations to be administered via inhalation. These aerosol formulations may be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They may also be formulated as pharmaceuticals for non-pressurized preparations, such as in a nebulizer or atomizer. Such spray formulations may also be used to spray mucous membranes.
[0088] An "effective amount" or a "therapeutically effective amount" refers to a dose sufficient to prevent or treat cancer in an individual. The amount that is effective for therapeutic or prophylactic use will depend, for example, on the stage and severity of the disease or condition being treated, the age, weight, and general health of the patient, and the judgment of the prescribing physician. The size of the dose will also be determined by the selected active, the method of administration, the timing and frequency of administration, the existence, nature, and extent of any adverse side effects that may accompany the administration of a particular active, and the desired physiological effect. Various diseases or conditions can be treated with the CAR materials of the present invention. It will be understood by those skilled in the art that extended treatment, possibly including multiple administrations, may be required at each or various rounds of administration used. By way of example, and without intending to limit the invention, the dose of the CAR material of the present invention may be from about 0.001 to about 1000 mg per kg of body weight of the subject to be treated per day, from about 0.01 to about 10 mg / kg body weight / day, from about 0.01 mg ... It may be about 1 mg / kg body weight / day. In one embodiment of the invention, the dose is about 1 mg / kg body weight / day. and about 1×10 expressing the CAR material of the present invention. 4 ~Approx. 1×10 8 When the CAR material of the present invention is a host cell, an exemplary dose of the host cells is at least 1 million cells (1 mg of cells / use). When the CAR material of the present invention is a nucleic acid packaged in a virus, an exemplary dose of virus can be 1 ng / dose.
[0089] For purposes of the present invention, the amount or dose of the CAR material of the present invention to be administered should be within a reasonable time frame. The dose should be sufficient to effect a therapeutic or prophylactic response in a subject or animal over a period of time from the time of administration. For example, a dose of the CAR material of the invention should be sufficient to bind to an antigen or to detect, treat or prevent a disease for a period of about 2 hours or more, e.g., about 12 to about 24 hours or more, from the time of administration. In some embodiments, the period may be even longer. The dose should be determined based on the efficacy of the particular CAR material of the invention and the condition of the animal (e.g., human), as well as the condition of the animal being treated. It is determined by the weight of the object (e.g., human).
[0090] For purposes of the present invention, for example, a set of mammals each given different doses of T cells Between animals, when a mammal is administered a certain dose of such T cells, the target cells The assay involves comparing the extent to which mammalian cells are lysed and / or IFN-g is secreted. The extent to which target cells are lysed and / or IFN-g is secreted when a certain dose is administered can be determined by methods known in the art. The antibody can be assayed by
[0091] In addition to the aforedescribed pharmaceutical compositions, the CAR materials of the present invention can be used in combination with, for example, cyclodextrins. The CAR materials of the present invention may be formulated as inclusion complexes, such as stringin inclusion complexes, or liposomes. Liposomes may serve to target the CAR materials of the present invention to specific tissues. Liposomes may also be used in the preparation of the CAR materials of the present invention. Many methods for preparing liposomes can be used to increase the half-life of CAR materials, as described, for example, in Szoka et al., Ann. Rev. Biophys. Bioeng., 9, 467 (1980), and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369. Methods are available.
[0092] Delivery systems that are useful in the context of the present invention may include sustained release, delayed release and sustained release delivery systems, so that delivery of the present composition occurs before the sensitization of the treated site and is sufficient time to cause sensitization.The present composition may be used together with other therapeutic agents or treatments.Such systems can avoid repeated administration of the present composition, thereby increasing convenience for subjects and physicians, and may be particularly suitable for some compositions of the present invention.
[0093] Many types of release delivery systems are available and known to those skilled in the art. These include polymer-based systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the aforementioned polymers containing drugs are described, for example, in U.S. Patent No. 5,075,109. Delivery systems include: Also included are non-polymeric systems, which are lipids including sterols such as cholesterol, cholesterol esters, and fatty acids or neutral fats such as monoglycerides, diglycerides, and triglycerides; hydrogel release systems; sylastic systems; peptide-based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; etc. Specific examples include: (a) active Erosion systems in which the composition is contained in the form of a matrix, e.g., U.S. Pat. No. 4,452,775 Nos. 4,667,014, 4,748,034 and 5,239,660, and (b) diffusion systems in which the active ingredient permeates through a polymer at a controlled rate, such as those described in U.S. Patent Nos. 3,832,253 and 3,854,480. In addition, pump-based hardware delivery systems may be used, some of which are adapted for injection.
[0094] Those skilled in the art will appreciate that the present invention provides a method for modifying the CAR material of the present invention so that the therapeutic or prophylactic effect of the material is increased by the modification. It will be readily appreciated that the disclosed CAR materials can be modified in any number of ways. For example, the CAR materials of the present invention can be conjugated to a target moiety either directly or indirectly via a binding moiety. The practice of conjugating compounds, e.g., the CAR materials of the present invention, to targeting moieties is well known in the art. These techniques are well known in the art, see, for example, Wadwa et al., J. Drug Targeting 3:111 (1995) and U.S. Patent No. 5,087,616.
[0095] The manner in which the CAR material of the present invention is released into the body after administration can be determined with respect to time and location within the body. The CAR material of the present invention can be modified into a depot form (see, for example, US Pat. No. 6,333,623) so that it can be regulated by the (See U.S. Patent No. 4,450,150.) A depot form of the CAR material of the invention can be, for example, an injectable composition that includes the CAR material of the invention and a porous or non-porous material, such as, for example, a polymer, in which the CAR material of the invention is encapsulated or disintegrated by decomposition of the material and / or the non-porous material. The depot is then injected into the desired location in the body, and the CAR material of the present invention diffuses at a predetermined rate. The drug is released from the implant at
[0096] When the CAR materials of the invention are administered with one or more additional therapeutic agents, the one or more additional Therapeutic agents can be co-administered to a mammal. "Co-administration" refers to the administration of one or more therapeutic agents sufficiently close in time that the CAR materials of the invention can enhance the effect of the additional therapeutic agent or agents, or vice versa. In this regard, the present invention relates to administering an additional therapeutic agent to a subject. The CAR material of the present invention can be administered first and one or more additional therapeutic agents can be administered second, or vice versa. Alternatively, the CAR material of the present invention and one or more additional therapeutic agents can be administered simultaneously.
[0097] Exemplary therapeutic agents that may be co-administered with the CAR materials are cytokines active on T cells, such as IL-2. IL-2 is believed to enhance the therapeutic effect of the CAR materials of the invention. Without being bound by theory or mechanism, IL-2 may mediate therapeutic outcomes by promoting in vivo expansion in numbers and / or effector function of cells expressing the CAR of the present invention. Other exemplary cytokines include IL-7 and IL-15. For purposes of the methods of the present invention, a host cell or cell population is administered to a mammal, and the cells may be allogeneic or autologous to the mammal.
[0098] The CAR material of the present invention is used in a method for treating or preventing a disease in a mammal. Without being bound by any particular theory or mechanism, it is believed that the CAR of the present invention can In this regard, one embodiment of the present invention is a method of treating or preventing cancer in a mammal, comprising administering to a mammal an effective amount of a CAR, nucleic acid, recombinant expression vector, host cell, cell population, antibody, and / or other polypeptide of the present invention, to a mammal. The present invention provides methods comprising administering the antigen-binding portion thereof, and / or the pharmaceutical composition to a mammal.
[0099] One embodiment of the present invention is to administer the CAR material of the present invention to a mammal. Examples of lymphodepletion include, but are not limited to, non-myelosuppressive lymphodepleting chemotherapy, myelosuppressive lymphodepleting chemotherapy, total body irradiation, and the like.
[0100] For the purposes of the methods of the present invention, a host cell or cell population is administered, which may be allogeneic or autologous to the mammal. Preferably, the cells are autologous to the mammal.
[0101] The mammals referred to herein may be any mammal. As used herein, the term "mammal" refers to any mammal, including, but not limited to, rodent mammals, such as mice and hamsters, and lagomorph mammals, such as rabbits. It refers to mammals. The mammal may be from the order Carnivora, including Felidae (cats) and Canidae (dogs). The mammal may be from the order Bovidae, including Bovidae (cattle) and Suidae (pigs), or from the order Equidae, including Equidae (horses). The mammal may be from the order Primates, Ceboids or Simoides (monkeys) or the order Anthropoids (humans and apes). Preferably, the mammal is a human.
[0102] In the context of the methods of the present invention, the cancer is an acute lymphocytic cancer, an acute myeloid leukemia (AML), a cytoplasmic cancer, or a myeloma. Focal rhabdomyosarcoma, bladder cancer (e.g., bladder cancer), bone cancer, brain cancer (e.g., medulloblastoma), breast cancer, cancer of the anus, anal canal, or anorectum, eye cancer, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic bone marrow cancer, colon cancer, esophageal cancer, cervical cancer, fibrosarcoma, gastrointestinal carcinoid tumor, cancer of the head and neck (e.g., head and neck squamous cell carcinoma), Hodgkin's lymphoma, hypopharyngeal Head cancer, kidney cancer, laryngeal cancer, leukemia, liquid tumors, liver cancer, lung cancer (e.g., non-small cell Lung cancer and lung adenocarcinoma), lymphoma, mesothelioma, mast cell tumor, melanoma, multiple myeloma, nasopharyngeal carcinoma, non-Hodgkin's lymphoma, chronic B-lymphocytic leukemia, hairy cell leukemia, acute lymphoblastic leukemia, The cancer may be any cancer, including allogeneic leukemia (ALL), and Burkitt's lymphoma, ovarian cancer, pancreatic cancer, peritoneal, omental and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, solid tumors, synovial sarcoma, gastric cancer, testicular cancer, thyroid cancer, and uterine cancer. Preferably, the cancer is characterized by expression of FLT3.
[0103] As used herein, the terms "treatment" and "prevention," and terms derived therefrom, do not necessarily mean 100% or complete treatment or prevention. Rather, there are various degrees of treatment or prevention that one of skill in the art recognizes as having potential benefit or therapeutic effect. In this regard, the methods of the present invention may provide any amount or level of treatment or prevention of cancer in a mammal. Moreover, the treatment or prevention provided by the methods of the present invention may include treatment or prevention of one or more conditions or symptoms of the disease, e.g., cancer, being treated or prevented. Also, for purposes of this specification, "prevention" may include delaying the onset of the disease, or its symptoms or conditions.
[0104] Another embodiment of the invention is a method for detecting the presence of cancer in a mammal, comprising: (a) administering to a mammal a sample comprising one or more cells derived from the mammal and a CAR, nucleic acid, recombinant expression vector, or a combination thereof; (b) contacting the vector, host cell, cell population, antibody and / or antigen-binding portion thereof, or pharmaceutical composition with the vector, host cell, cell population, antibody and / or antigen-binding portion thereof, or pharmaceutical composition, thereby forming a complex; and (b) detecting the complex in a mammal. detecting the complex, which indicates the presence of cancer in the subject.
[0105] Another embodiment of the invention includes a method of determining whether a subject having a proliferative disease is a candidate for treatment with a chimeric antigen receptor comprising an antigen binding domain specific for FLT3, the method comprising measuring the expression level of FLT3 in a biological sample from the subject; and determining whether the expression level of FLT3 in the biological sample is increased compared to a sample from a subject not having a proliferative disease (control).
[0106] The sample may be obtained by any suitable method, e.g., biopsy or autopsy. A biopsy is the removal of tissue and / or cells from an individual. Such removal may be the collection of tissue and / or cells from an individual in order to perform experiments on the removed tissue and / or cells. The experiments may include experiments to determine whether the individual has and / or is suffering from a condition or disease state. The condition or disease may be, e.g., cancer.
[0107] With respect to one embodiment of the method of the present invention for detecting the presence of a proliferative disease, e.g., cancer, in a mammal, the sample comprising mammalian cells can be a sample comprising whole cells, a lysate thereof, or a fraction of a lysate of a whole cell, e.g., a nuclear or cytoplasmic fraction, a total protein fraction, or a nucleic acid fraction. When the sample comprises whole cells, the cells can be any cell of a mammal, e.g., a blood cell or an endogenous cell. The cells may be cells of any organ or tissue, including epithelial cells.
[0108] The contacting can be performed in vitro or in vivo with respect to a mammal. Preferably, the contacting is in vitro.
[0109] Detection of the complex can also be performed by any number of methods known in the art, such as the CAR, polypeptide, protein, nucleic acid, or the like of the present invention described herein. The recombinant expression vector, host cell, cell population, or antibody or antigen-binding portion thereof may be, for example, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase, The antibody is labeled with a detectable label such as beta-peroxidase (BPO) and an elemental particle (e.g., gold particle). obtain.
[0110] How can we test CARs for their ability to recognize target cells and for antigen specificity? Methods for measuring the release of cytokines (e.g., interferon-γ, granulocyte / monocyte colony-stimulating factor (GM-CSF), tumor necrosis factor a (TNF-α), or interleukin 2 (IL-2)) are known in the art. For example, Clay et al., J. Immunol., 163:507-513 (1999) teaches methods for measuring the release of cytokines (e.g., interferon-γ, granulocyte / monocyte colony-stimulating factor (GM-CSF), tumor necrosis factor a (TNF-α), or interleukin 2 (IL-2)). Furthermore, the function of CARs is described in Zhao et al., J. Immunol., 174:4415-4423 (2005). This can be assessed by measuring cellular cytotoxicity, as described above.
[0111] Another embodiment of the invention relates to a CAR, a nucleic acid, a recombinant expression vector, a host cell, a cell population, an antibody or a CAR-specific antibody of the invention for treating or preventing a proliferative disease, e.g., cancer, in a mammal. Use of an antigen-binding portion thereof and / or a pharmaceutical composition thereof are provided. The cancer may be any of the cancers described herein. Preferably, the cancer is a pre-B cell precursor acute lymphoblastic blastoma. Myeloid leukemia or acute myeloid leukemia.
[0112] It should be noted that the above are merely examples of embodiments. Other exemplary embodiments will be apparent from the entire description of this specification. It will also be understood by those skilled in the art that each of these embodiments can be used in various combinations with the other embodiments provided herein.
[0113] Certain aspects of the present invention are given below. 1. FLT3-specific antigen-binding domain, transmembrane domain, and intracellular T cell signaling domain Main-containing chimeric antigen receptor (CAR). 2. Aspect 1, in which the antigen-binding domain comprises a light chain variable region comprising a sequence of SEQ ID NO: 13 to 19 The CAR described in. 3. The CAR of aspect 1 or 2, wherein the antigen-binding domain comprises a heavy chain variable region comprising a sequence of SEQ ID NO:5 to 11. 4. Any one of aspects 1 to 3, wherein the antigen-binding domain comprises a linker sequence of SEQ ID NO: 12. The CAR described in. 5. The CAR according to any one of aspects 1 to 4, wherein the antigen-binding domain comprises SEQ ID NOs: 5 to 19. . 6. The CAR of any one of aspects 1 to 5, wherein the transmembrane domain comprises a CD8 amino acid sequence. . 7. The transmembrane domain comprises a CD8α hinge sequence of SEQ ID NO: 25 and a transmembrane domain of SEQ ID NO: 26. 7. The CAR of any one of aspects 1 to 6, comprising a CD8 amino acid sequence, including a sequence of 8. The intracellular T cell signaling domain comprises 4-1BB, CD3 zeta, or both. 8. A CAR according to any one of claims 1 to 7. 9. The CAR of any one of aspects 1-8, wherein said intracellular T cell signaling domain comprises the amino acid sequence of 4-1BB of SEQ ID NO: 27. 10. The CAR of any one of aspects 1-9, wherein the intracellular T cell signaling domain comprises the amino acid sequence of CD3 zeta in SEQ ID NO: 28. 11. Any one of aspects 1 to 10, wherein the CAR further comprises a spacer comprising SEQ ID NO: 21 to 24. The CAR described in one. 12. The CAR of embodiment 1, wherein the CAR comprises any one of the sequences of SEQ ID NOs: 1, 2, 29, or 30. 13. A nucleic acid comprising a nucleotide sequence encoding a CAR according to any one of aspects 1 to 12. . 14. The nucleic acid of aspect 13, wherein the nucleotide sequence is codon optimized. 15. A recombinant expression vector comprising a nucleic acid according to embodiment 13 or 14. 16. The recombinant expression vector of aspect 15, wherein said recombinant expression vector is a lentiviral vector. 17. An isolated host cell comprising a recombinant expression vector according to embodiment 15 or 16. 18. A cell population comprising at least one host cell according to embodiment 17. 19. An antibody or antigen binding thereof that specifically binds to a CAR according to any one of aspects 1 to 12. portion. 20. A pharmaceutical composition comprising a CAR according to any one of aspects 1 to 12, a nucleic acid according to aspect 13 or 14, a recombinant expression vector according to aspect 15 or 16, a host cell according to aspect 17, a cell population according to aspect 18, or an antibody or antigen-binding portion thereof according to aspect 19, and a pharma- ceutical acceptable carrier. 21. A method for detecting the presence of cancer, comprising: (a) contacting a sample comprising one or more cells with a CAR according to any one of aspects 1 to 12, a nucleic acid according to aspect 13 or 14, a recombinant expression vector according to aspect 15 or 16, a host cell according to aspect 17, a cell population according to aspect 18, an antibody or antigen-binding portion thereof according to aspect 19, or a pharmaceutical composition according to aspect 20, thereby forming a complex; and (b) detecting a complex, wherein detection of the complex is indicative of the presence of cancer. A method comprising: 22. The cancer is pre-B cell precursor acute lymphoblastic leukemia or acute myeloid leukemia. 22. The method of claim 21, 23. A method according to any one of claims 1 to 12 for use in treating or preventing cancer in a mammal. the CAR according to any one of the preceding claims, the nucleic acid according to embodiment 13 or 14, or the recombinant an expression vector according to aspect 17, a host cell according to aspect 18, an antibody or antigen-binding portion thereof according to aspect 19, or a pharmaceutical composition according to aspect 20. 24. The cancer is pre-B cell precursor acute lymphoblastic leukemia or acute myeloid leukemia. 24. The CAR, nucleic acid, recombinant expression vector, host cell, cell population, antibody or or an antigen-binding portion thereof, or a pharmaceutical composition thereof. 25. A method for determining whether a subject having a proliferative disease is a candidate for treatment with a chimeric antigen receptor comprising an antigen-binding domain specific for FLT3, the method comprising: measuring the expression level of FLT3 in a biological sample derived from the subject; and determining whether the expression level of FLT3 in the biological sample is increased compared to a sample derived from a subject (control) who does not have a proliferative disease.
[0114] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope. EXAMPLES
[0115] Example 1 This example demonstrates that FLT3 is expressed on acute lymphoblastic and acute myeloid leukemia cell lines. The number of FLT3 receptors per cell was determined using BD Quantibrite beads (BD Quantibrite beads, as per the manufacturer's protocol). Flow cytometry was performed using anti-human CD135 (FLT3) antibody (eBioscience; San Jose, CA, USA) and phycoerythrin (PE)-conjugated anti-human CD135 (FLT3) antibody (eBioscience; San Diego, CA, USA; clone BV10A4H2). By cytometry, a variety of acute lymphoblastic [NALM6 (DSMZ no. ACC 128), HB11;19 (Horsley et al., Genes Chromosomes Cancer, 45:554-564 (2006)), KOPN-8 (DSMZ no. ACC 552), SEM (DSMZ no. ACC 546)] and acute myeloid [MOLM13 (DSMZ no. ACC 554), MOLM14 (DSMZ no. ACC 555)] were identified. MV4;11 (DSMZ no. ACC 577), MV4;11 (DSMZ no. ACC 102), and THP-1 (DSMZ no. ACC 16)] leukemia cell lines. KOPN-8 is a cell line derived from a patient with infantile ALL. DSMZ is a cell line derived from a patient with ALL. Nitz Institute - DSMZ German Collection of Microbial Cell Cultures (DSMZ) (Braunschweig, Germany). 10% heat-inactivated fetal bovine serum (Omega Scientific; Tarzana, CA, USA), 100 U / mL Peptide All cell lines were cultured using RPMI 1640 (Invitrogen; Carlsbad, CA, USA) medium supplemented with nicotinic acid, 100 mg / mL streptomycin, and 2 mM L-glutamine (Invitrogen). Labeled samples were analyzed by flow cytometry on a BD LSR Fortessa (BD Biosciences) and data analysis was performed using FlowJo software (FlowJo LLC, Ashland, OR, USA) and GraphPad Prism (GraphPad Software; La Jolla, CA, USA). Figure 1 shows the results.
[0116] Example 2 This example demonstrates the generation of CARs according to an embodiment of the invention. The amino acid sequence encoding FLT3 scFv was converted to a DNA sequence, codon optimized, and submitted to GeneArt TMThe DNA was synthesized using gene synthesis (ThermoFisher Scientific; Waltham, MA, USA) with a Kozak sequence, a membrane localization leader sequence derived from human granulocyte-macrophage colony-stimulating factor (GM-CSF), a 5' NheI restriction site, and a 3' BspEI restriction site. TM From the vector, the FLT3 scFv sequence was subcloned and transferred using standard molecular cloning techniques into the third generation lentiviral plasmid pELNS-19BB zeta, which contains the CD8 hinge and transmembrane domains, the 4-1BB signaling domain, and the CD3 zeta domain, using the NheI and BspEI cloning sites. Figure 2 shows a schematic diagram of the CAR (left side of the figure). CAR was SEQ ID NO: 1 / 29. The leader sequence is initially encoded and facilitates transport to the cell surface; it appears to be excised in the mature form.
[0117] Generation of lentiviral supernatant: 293T cells (ATCC; Manassas, VA, USA; ATCC number CRL-3216) were transiently transfected with third-generation lentiviral plasmids to produce the virus. The supernatant was generated. 293T cells were plated in poly-D-lysine-coated 15 cm tissue culture plates (Corning; Tewksbury, MA, USA) in DMEM supplemented with 10% heat-inactivated fetal bovine serum (Omega Scientific), 100 U / mL penicillin, 100 mg / mL streptomycin, and 2 mM L-glutamine (Invitrogen) and allowed to adhere for 16 h. The following day, plasmids containing GFP or FLT3 CAR, pMDLg / pRRE and pRSV-Rev packaging, and pMD-G envelope plasmids were lipid-transfected into 293T cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer's protocol. Transfection mixture After addition of 100 μg / ml, the medium containing the transfection mixture was discarded and replaced with fresh medium 4 to 6 hours after addition. At 24, 48, and 72 hours after transfection, viral supernatants were harvested, centrifuged at 1200 rpm for 6 minutes to remove cells, and stored at -80°C until use.
[0118] Source of T cells: Purified human lymphocytes derived from healthy donors were used as the source of T cells for the experiments, and were approved by the NIH IRB after informed consent according to the Declaration of Helsinki. The materials were obtained from the Department of Transfusion Medicine at the NIH Clinical Center under a protocol approved by the manufacturer. Donor lymphocytes were isolated using lymphocyte separation medium (Lonza; Basel, Switzerland) according to protocol. Red blood cells were removed from the blood and the blood was frozen in heat-inactivated fetal bovine serum (FBS; Omega Scientific) containing 10% dimethyl sulfoxide (DMSO; Sigma Aldrich; St Louis, MO, USA) and stored in liquid nitrogen.
[0119] T cell transduction: Purified lymphocytes were thawed and cultured with Dynabeads Human T-Expander CD3 / CD28 beads (Invitrogen) at a bead:cell ratio of 3:1 in T cell expansion medium (TCEM) consisting of AIM-V medium (Invitrogen) supplemented with 5% heat-inactivated FBS (Omega Scientific), 100 U / mL penicillin, 100 mg / mL streptomycin, 15 mM HEPES, and 2 mM L-glutamine (Invitrogen), and 40 IU / ml IL-2. Prior to transduction with viral supernatant, Cells were cultured for 2 days. Two million T cells were plated per well of a 6-well plate in 1 ml TCEM + 3 ml viral supernatant containing final concentrations of 40 IU / mL IL-2 and 10 mg / mL protamine sulfate. The 6-well plate of T cells was centrifuged at 872g for 2 hours at 32°C, then The plates were then incubated at 37°C overnight. The following day, the Dynabeads were removed using a magnetic rack. The cells were removed and T cells were cultured at 500,000 cells / ml in fresh TCEM containing 300 IU / mL IL2. T cells were cultured in TCEM containing 300 IU / mL IL2 until day 9, maintaining cells at less than 1 million per ml, and T cell transduction was measured by flow cytometry.
[0120] Example 3 This example demonstrates the transduction of FLT3 CAR T cells according to an embodiment of the invention. The CAR was SEQ ID NO: 1 / 29. The leader sequence is encoded initially and facilitates transport to the cell surface; it appears to be excised in the mature form. The transduction efficiency of the transduced T cells was determined in T cell cultures on day 9. As shown in the left panel of Figure 3, the transduction efficiency was determined by flow cytometry using an LSR Fortessa (BD Biosciences). According to Lee, GFP-transduced T cells were analyzed for GFP positivity (87.8% positive). Protein L (Genscript; Piscataway, NJ, USA), a bacterial protein that binds to a subset of the kappa light chains of antibodies, was used to measure the expression of FLT3 CAR. The NC7-based FLT3 CAR is a sequence that binds to Protein L, and the expression of the CAR can be measured by staining with streptavidin PE (middle panel of FIG. 3, 77.1% positive). As a negative control, FLT3 CAR T cells were stained with streptavidin PE (secondary) alone (right panel of FIG. 3). (Panel of 1, 0% positive). Data analysis was performed using FlowJo software (FlowJo LLC). .
[0121] Example 4 This example demonstrates that, in accordance with an embodiment of the present invention, T cells expressing FLT3-targeting chimeric antigen receptors secrete high levels of cytokines when co-cultured with FLT3-expressing cell lines. This paper demonstrates that Cytokine production assay: Transduced with GFP or CAR as determined in Example 1 The CAR T cells were co-cultured with various ALL and AML cell lines with different expression of FLT3. Using the acute lymphoblastic and acute myeloid leukemia lines listed in Example 1 as target tumor cell lines, it was demonstrated that FLT3 CAR T cells express interleukin-1 (IL-1) in response to target recognition and CAR T cell activation. Measures the ability to produce interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) The CAR was sequence number 1 / 29. The leader sequence is initially encoded and facilitates transport to the cell surface; it appears to be excised in the mature form. T cells (100,000) and leukemia cells (100,000) were cultured per well of a 96-well plate in 10% heat-inactivated fetal bovine serum (Omega Scientific), 100 U / mL penicillin, 100 mg / mL streptomycin, and 2 mM The plates were then co-incubated for 16 hours in RPMI 1640 (Invitrogen) medium (200 mL per well) supplemented with 100 mL of L-glutamine (Invitrogen). The following day, the plates were rotated at 1200 rpm for 6 minutes, After centrifugation, 150 mL of the supernatant was carefully removed for analysis by enzyme-linked immunosorbent assay (ELISA). IFN-gamma was analyzed by human IFN-gamma Quantikine ELISA (R&D systems; Minneapolis, MN, USA) using a Spectramax M5 microcentrifuge according to the manufacturer's protocol. The plate was read using a plate reader (Molecular Devices; Sunnyvale, CA, USA). For the assay, human IL-2 Quantikine ELISA (R&D systems; Minneapolis, MN) was used according to the manufacturer's protocol and read on a Spectramax M5 microplate reader (Molecular Devices). The data was then plotted using GraphPad Prism (GraphPad Software). Figures 4-7 show the results.
[0122] Example 5 This example demonstrates that embodiments of the present invention allow T cells expressing a FLT3-targeting CAR to reduce FLT3-expressing ALL in vivo, and that the in vivo use of FLT3 CAR T cells T cells expressing FLT3-targeting CARs express FLT3 in vivo The aim of this study is to demonstrate that treatment with cyclophosphamide can slow the progression of currently diagnosed AML. Animal studies conducted under protocols approved by the NCI Bethesda Animal Care and Use Committee. One million luciferase-positive ALL or AML cell lines were transfected into NSG mice (NOD scid gamma, NOD.Cg-Prkdc scid Il2rg tm1Wjl Leukemia progression was monitored by bioluminescence using a Xenogen IVIS Lumina imaging system (Caliper Life Sciences; Hopkinton, MA, USA). Following intraperitoneal (IP) injection with 3 mg of D-luciferin (Caliper Life Sciences) for 4 min, leukemia-bearing NSG mice were imaged for 4 min. Bioluminescence signals (photons / sec / cm) from leukemia-bearing animals were analyzed using Living Image software (Caliper Life Sciences). 2 / sr) were analyzed. When detectable amounts of leukemia were observed, T cells transduced with GFP or FLT3 CAR were injected on the same day and leukemia progression or regression was measured twice weekly, as described below. The CAR was SEQ ID NO: 1 / 29. The leader sequence was initially encoded and was used to target the leukemia to the cell surface. It promotes transport; it appears to be excised in the mature form. IV injection of SEM ALL cells: 7.5 × 10 6 of GFP-transduced T cells (67% transduced) or FLT3-CAR-transduced T cells (50% transduced) on day 4 (when detectable amounts of leukemia were observed). The subjects were injected with 100 mg of leukemia serum and the progression or regression of leukemia was measured. The results are shown in Figure 8 (minutes / max photons / seconds / cm 2 / sr signal:8.00e4 / 8.00e6). IV injection of SEM ALL cells: 10 × 10 6 GFP-transduced T cells, or 10 x 10 6 , 5×10 6 If 1×10 6 FLT3 CAR-transduced T cells were cultured at day 14 (when detectable amounts of leukemia were observed). The mice were injected at 100 nm to 150 nm cerebrospinal fluid (milligrams) ... and the progression or regression of leukemia was measured. The results are shown in Figure 9 (minutes / maximum photons / second / cm 2 / sr signal:5.00e4 / 8.00e6). IV injection of MOLM13 AML cells: 7 × 10 6 GFP-transduced T cells or FLT3 CAR-transduced T cells were injected on day 6 (when detectable amounts of leukemia were observed) and leukemia progression or regression was measured. The results are shown in Figure 10 (min / max photons / sec / cm 2 / sr signal:5.00e4 / 8.00e6). IV injection of MOLM14 AML cells: 7 × 10 6 GFP-transduced T cells or FLT3 CAR-transduced T cells were injected on day 6 (when detectable amounts of leukemia were observed) and leukemia progression or regression was measured. The results are shown in Figure 11 (min / max photons / sec / cm2 / sr signal:5.00e4 / 8.00e6).
[0123] All references cited in this specification, including publications, patent applications, and patents, are herein incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference herein, and were set forth in their entirety herein.
[0124] The terms "a" and "b" in the context of describing the present invention (especially in the context of the claims below) The use of "an," "the," and "at least one" and similar referents should be construed as including both the singular and the plural unless otherwise indicated herein or clearly contradicted by context. The use of "one" (e.g., "at least one of A and B") is intended to be limiting unless otherwise stated herein. means one item selected from the list (A or B), or any combination of two or more of the items listed (A and B), unless otherwise specified or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are used interchangeably throughout the appended claims, unless otherwise specified. These terms should be construed as open-ended terms (i.e., meaning "including, but not limited to"). Recitation of ranges is merely intended to serve as a shorthand method of referring individually to each separate value within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if each was individually recited. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is merely intended to serve as a shorthand method of referring individually to each separate value within the range, and each separate value is incorporated into the specification as if each separate value were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is merely intended to serve as a shorthand method of referring individually to each separate value within the range, It is intended to be descriptive and is not intended to impose limitations on the scope of the invention unless specifically claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0125] Preferred embodiments of the invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of these preferred embodiments may become apparent to those of skill in the art upon reading the foregoing description. The inventors anticipate that such variations will be employed by those of skill in the art, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, this invention encompasses any combination of the above-described elements in all possible variations thereof unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
1. A chimeric antigen receptor (CAR) comprising an antigen-binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain, (a) the antigen-binding domain comprises a light chain variable region comprising a sequence of SEQ ID NO: 13-19; or (b) the antigen-binding domain comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 5-11; C.A.R.
2. The CAR of claim 1, wherein the antigen-binding domain comprises a light chain variable region comprising a sequence of SEQ ID NO: 13-19.
3. The CAR according to claim 1 or 2, wherein the antigen-binding domain comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 5 to 11.
4. The CAR of any one of claims 1 to 3, wherein the antigen-binding domain comprises a linker sequence of SEQ ID NO:
12.
5. The CAR of any one of claims 1 to 4, wherein the antigen-binding domain comprises SEQ ID NO: 5 to 19.
6. The CAR of any one of claims 1 to 5, wherein the transmembrane domain comprises a CD8 amino acid sequence.
7. The CAR of any one of claims 1 to 6, wherein the transmembrane domain comprises a CD8 amino acid sequence comprising a CD8α hinge sequence of SEQ ID NO:25 and a transmembrane domain sequence of SEQ ID NO:
26.
8. The CAR of any one of claims 1 to 7, wherein the intracellular T cell signaling domain comprises 4-1BB, CD3 zeta, or both.
9. The CAR of any one of claims 1 to 8, wherein the intracellular T cell signaling domain comprises an amino acid sequence of 4-1BB of SEQ ID NO:
27.
10. The CAR of any one of claims 1 to 9, wherein the intracellular T cell signaling domain comprises the amino acid sequence of CD3 zeta of SEQ ID NO:
28.
11. The CAR according to any one of claims 1 to 10, further comprising a spacer comprising SEQ ID NO: 21 to 24.
12. 1, wherein the CAR comprises any one of the sequences of SEQ ID NO: 1, 2, 29, or 30. A CAR described in.
13. A nucleic acid comprising a nucleotide sequence encoding the CAR according to any one of claims 1 to 12.
14. The nucleic acid of claim 13, wherein the nucleotide sequence is codon optimized.
15. A recombinant expression vector comprising the nucleic acid of claim 13 or 14.
16. The recombinant expression vector of claim 15, wherein the recombinant expression vector is a lentiviral vector.
17. 17. An isolated host cell comprising a recombinant expression vector according to claim 15 or 16.
18. A cell population comprising at least one host cell according to claim 17.
19. An antibody or an antigen-binding portion thereof that specifically binds to the CAR according to any one of claims 1 to 12.
20. A pharmaceutical composition comprising the CAR according to any one of claims 1 to 12, the nucleic acid according to claim 13 or 14, the recombinant expression vector according to claim 15 or 16, the host cell according to claim 17, the cell population according to claim 18, or the antibody or antigen-binding portion thereof according to claim 19, and a pharma- ceutical acceptable carrier.
21. 1. A method for detecting the presence of cancer, comprising: (a) contacting a sample comprising one or more cells with the CAR according to any one of claims 1 to 12, the nucleic acid according to claim 13 or 14, the recombinant expression vector according to claim 15 or 16, the host cell according to claim 17, the cell population according to claim 18, the antibody or antigen-binding portion thereof according to claim 19, or the pharmaceutical composition according to claim 20, thereby forming a complex; and (b) detecting a complex, wherein detection of the complex is indicative of the presence of cancer. A method comprising:
22. 22. The method of claim 21, wherein the cancer is pre-B cell precursor acute lymphoblastic leukemia or acute myeloid leukemia.
23. 20. The CAR according to any one of claims 1 to 12, the nucleic acid according to claim 13 or 14, the recombinant expression vector according to claim 15 or 16, the host cell according to claim 17, the cell population according to claim 18, the antibody or antigen-binding portion thereof according to claim 19, or the pharmaceutical composition according to claim 20, for use in treating or preventing cancer in a mammal.
24. 24. The CAR, nucleic acid, recombinant expression vector, host cell, cell population, antibody or antigen-binding portion thereof, or pharmaceutical composition of claim 23, wherein the cancer is pre-B cell precursor acute lymphoblastic leukemia or acute myeloid leukemia.
25. 25. The method of claim 21 or 22, or the CAR, nucleic acid, recombinant expression vector, host cell, cell population, antibody or antigen-binding portion thereof, or pharmaceutical composition of claim 23 or 24 for use as claimed in claim 23 or 24, the method further comprising measuring the expression level of FLT3 in a biological sample derived from the mammal; and determining whether the expression level of FLT3 in the biological sample is increased compared to a sample derived from a control mammal not having a proliferative disease.
